CARsgen to Present CT0596 and CT1190B Allogeneic CAR-T Data at the 2026 EHA Congress

Bulletin Express04-27

CARSgen Therapeutics Holdings Limited (CARsgen-B, 02171) disclosed that two investigator-initiated trials (IITs) have been selected for poster presentation at the 2026 Annual Congress of the European Hematology Association (EHA).

The accepted abstracts cover: 1. CT0596 – an allogeneic BCMA-targeted CAR-T therapy for refractory/relapsed multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Preliminary IIT results show favorable tolerability and encouraging efficacy signals. Phase Ib trials in R/R MM and primary PCL are planned for 2026. 2. CT1190B – an allogeneic CD19/CD20-targeted CAR-T therapy under evaluation for refractory/relapsed B-cell non-Hodgkin lymphoma (R/R B-NHL). Additional IITs are assessing the candidate in moderate-to-severe refractory systemic lupus erythematosus and refractory/progressive systemic sclerosis. A Phase Ib study in R/R B-NHL is also scheduled for 2026.

Both candidates are developed on CARsgen’s proprietary THANK-u Plus™ platform, which is designed to enhance safety, efficacy, and manufacturing efficiency across hematologic malignancies, solid tumors, and autoimmune diseases.

Abstracts detailing clinical data will be released by EHA on 12 May 2026 at 15:30 CEST, with further information to be provided on the company’s website.

CARsgen emphasizes that successful development and commercialization of CT0596 and CT1190B remain subject to clinical progress and regulatory outcomes, and advises shareholders to exercise caution when dealing in its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158525514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158525514","market":"us","top_or_hot":-1,"title":"CARsgen to Present CT0596 and CT1190B Allogeneic CAR-T Data at the 2026 EHA Congress","media":"Bulletin Express","content":"<p>CARSgen Therapeutics Holdings Limited (CARsgen-B, 02171) disclosed that two investigator-initiated trials (IITs) have been selected for poster presentation at the 2026 Annual Congress of the European Hematology Association (EHA).</p>\n<p>The accepted abstracts cover:\n1. CT0596 – an allogeneic BCMA-targeted CAR-T therapy for refractory/relapsed multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Preliminary IIT results show favorable tolerability and encouraging efficacy signals. Phase Ib trials in R/R MM and primary PCL are planned for 2026.\n2. CT1190B – an allogeneic CD19/CD20-targeted CAR-T therapy under evaluation for refractory/relapsed B-cell non-Hodgkin lymphoma (R/R B-NHL). Additional IITs are assessing the candidate in moderate-to-severe refractory systemic lupus erythematosus and refractory/progressive systemic sclerosis. A Phase Ib study in R/R B-NHL is also scheduled for 2026.</p>\n<p>Both candidates are developed on CARsgen’s proprietary THANK-u Plus™ platform, which is designed to enhance safety, efficacy, and manufacturing efficiency across hematologic malignancies, solid tumors, and autoimmune diseases.</p>\n<p>Abstracts detailing clinical data will be released by EHA on 12 May 2026 at 15:30 CEST, with further information to be provided on the company’s website.</p>\n<p>CARsgen emphasizes that successful development and commercialization of CT0596 and CT1190B remain subject to clinical progress and regulatory outcomes, and advises shareholders to exercise caution when dealing in its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARsgen to Present CT0596 and CT1190B Allogeneic CAR-T Data at the 2026 EHA Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARsgen to Present CT0596 and CT1190B Allogeneic CAR-T Data at the 2026 EHA Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-27 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSgen Therapeutics Holdings Limited (CARsgen-B, 02171) disclosed that two investigator-initiated trials (IITs) have been selected for poster presentation at the 2026 Annual Congress of the European Hematology Association (EHA).</p>\n<p>The accepted abstracts cover:\n1. CT0596 – an allogeneic BCMA-targeted CAR-T therapy for refractory/relapsed multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Preliminary IIT results show favorable tolerability and encouraging efficacy signals. Phase Ib trials in R/R MM and primary PCL are planned for 2026.\n2. CT1190B – an allogeneic CD19/CD20-targeted CAR-T therapy under evaluation for refractory/relapsed B-cell non-Hodgkin lymphoma (R/R B-NHL). Additional IITs are assessing the candidate in moderate-to-severe refractory systemic lupus erythematosus and refractory/progressive systemic sclerosis. A Phase Ib study in R/R B-NHL is also scheduled for 2026.</p>\n<p>Both candidates are developed on CARsgen’s proprietary THANK-u Plus™ platform, which is designed to enhance safety, efficacy, and manufacturing efficiency across hematologic malignancies, solid tumors, and autoimmune diseases.</p>\n<p>Abstracts detailing clinical data will be released by EHA on 12 May 2026 at 15:30 CEST, with further information to be provided on the company’s website.</p>\n<p>CARsgen emphasizes that successful development and commercialization of CT0596 and CT1190B remain subject to clinical progress and regulatory outcomes, and advises shareholders to exercise caution when dealing in its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1158525514","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158525514","pubTimestamp":1777289122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CARSgen Therapeutics Holdings Limited (CARsgen-B, 02171) disclosed that two investigator-initiated trials (IITs) have been selected for poster presentation at the 2026 Annual Congress of the European...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"科济康将在2026年EHA大会上展示CT0596和CT1190B同种异体CAR-T数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARSgen Therapeutics Holdings Limited (CARsgen-B, 02171) disclosed that two investigator-initiated trials (IITs) have been selected for poster presentation at the 2026 Annual Congress of the European Hematology Association (EHA).\nThe accepted abstracts cover:\n1. CT0596 – an allogeneic BCMA-targeted CAR-T therapy for refractory/relapsed multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Preliminary IIT results show favorable tolerability and encouraging efficacy signals. Phase Ib trials in R/R MM and primary PCL are planned for 2026.\n2. CT1190B – an allogeneic CD19/CD20-targeted CAR-T therapy under evaluation for refractory/relapsed B-cell non-Hodgkin lymphoma (R/R B-NHL). Additional IITs are assessing the candidate in moderate-to-severe refractory systemic lupus erythematosus and refractory/progressive systemic sclerosis. A Phase Ib study in R/R B-NHL is also scheduled for 2026.\nBoth candidates are developed on CARsgen’s proprietary THANK-u Plus™ platform, which is designed to enhance safety, efficacy, and manufacturing efficiency across hematologic malignancies, solid tumors, and autoimmune diseases.\nAbstracts detailing clinical data will be released by EHA on 12 May 2026 at 15:30 CEST, with further information to be provided on the company’s website.\nCARsgen emphasizes that successful development and commercialization of CT0596 and CT1190B remain subject to clinical progress and regulatory outcomes, and advises shareholders to exercise caution when dealing in its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158525514","isCrawlerRequest":true}